Country: United States
Language: English
Source: NLM (National Library of Medicine)
RANITIDINE HYDROCHLORIDE (UNII: BK76465IHM) (RANITIDINE - UNII:884KT10YB7)
Teligent Pharma, Inc.
INTRAVENOUS
PRESCRIPTION DRUG
ZANTAC Injection is indicated in some hospitalized patients with pathological hypersecretory conditions or intractable duodenal ulcers, or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication. ZANTAC Injection is contraindicated for patients known to have hypersensitivity to the drug.
ZANTAC® Injection, 25 mg/mL, containing phenol 0.5% as preservative, is available as follows: NDC 52565-101-25, 2 mL single-dose vials (Carton of 25) NDC 52565-102-05, 6 mL multidose vials (Carton of 5) Store between 4° and 25°C (39° and 77°F); excursions permitted to 30°C (86°F). Protect from light. Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat; however, brief exposure up to 40°C does not adversely affect the product. Protect from freezing. Manufactured by : Teligent Pharma, Inc. Buena, NJ 08310 ZANTAC® is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc., used under license. MULTISTIX® is a registered trademark of Bayer Healthcare LLC. PI-ZAN-00 Rev 04/2019
New Drug Application
ZANTAC- RANITIDINE HYDROCHLORIDE INJECTION, SOLUTION TELIGENT PHARMA, INC. ---------- ZANTAC (RANITIDINE) INJECTION RX ONLY DESCRIPTION The active ingredient in ZANTAC Injection is ranitidine hydrochloride (HCl), a histamine H -receptor antagonist. Chemically it is N[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N′-methyl-2- nitro-1,1-ethenediamine, hydrochloride. It has the following structure: The empirical formula is C H N O S●HCl, representing a molecular weight of 350.87. Ranitidine HCl is a white to pale yellow, granular substance that is soluble in water. ZANTAC Injection is a clear, colorless to yellow, nonpyrogenic liquid. The yellow color of the liquid tends to intensify without adversely affecting potency. The pH of the injection solution is 6.7 to 7.3. STERILE INJECTION FOR INTRAMUSCULAR OR INTRAVENOUS ADMINISTRATION Each 1 mL of aqueous solution contains ranitidine 25 mg (equivalent to 28 mg ranitidine hydrochloride, USP); phenol 5 mg as preservative; and 0.96 mg of monobasic potassium phosphate and 2.4 mg of dibasic sodium phosphate as buffers. CLINICAL PHARMACOLOGY ZANTAC is a competitive, reversible inhibitor of the action of histamine at the histamine H -receptors, including receptors on the gastric cells. ZANTAC does not lower serum Ca++ in hypercalcemic states. ZANTAC is not an anticholinergic agent. PHARMACOKINETICS _ABSORPTION:_ ZANTAC is absorbed very rapidly after intramuscular (IM) injection. Mean peak levels of 576 ng/mL occur within 15 minutes or less following a 50-mg IM dose. Absorption from IM sites is virtually complete, with a bioavailability of 90% to 100% compared with intravenous (IV) administration. Following oral administration, the bioavailability of ZANTAC Tablets is 50%. _DISTRIBUTION:_ The volume of distribution is about 1.4 L/kg. Serum protein binding averages 15%. _METABOLISM:_ In humans, the N-oxide is the principal metabolite in the urine; however, this amounts to <4% of the dose. Other metabolites are the S-oxide (1%) and the desmethyl ranitidine (1%) Read the complete document